跳至主要内容
临床试验/NCT02614313
NCT02614313已完成不适用

Assessment of Psychological and Metabolic Responses During Fructose Intolerance Breath Tests in Patients With Functional GI Disorders: Placebo-controlled Breath Testing

Brain-Gut Research Group1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年6月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Fructose intolerance, as percentage of patients

研究概览

简要总结

Background: Breath testing for food intolerances is becoming routine in patients with functional gastrointestinal disorders (FGID). Both FGID and saccharide intolerances (FODMAPs: fermentable oligo-, di-, polysaccharide and polyols, e.g. lactose, fructose, sorbitol) are common (>10% of any given population) and often respond to dietary modification. The breath tests are based on quantification of gas excretion in breath as a sign of malabsorption and symptom provocation, but are likely subject to considerable psychological bias. The role of expectation and other psychological effects on breath testing has not been reported, but is crucial for the validation of these increasingly wide-spread tests with considerable dietary and potentially deleterious consequences. Fructose has been shown to result in short term pro-inflammatory metabolic responses, but these effects have not been studied as underlying causes for intolerance symptoms in fructose intolerant patients with FGID.

Aim: To investigate the psychological component and the short-term metabolic effects of fructose breath testing in patients referred for evaluation of FGID using placebo. Additionally, to assess baseline predictors for a positive breath test result.

Methods: Fructose intolerance (defined by a positive symptom index) and malabsorption (defined by increased breath hydrogen/methane concentrations) will be determined in 30 successive male and female FGID in a single centre using breath-testing. Fructose 35g, given double-blind as well as open, a sweet placebo (cyclamate/saccharine; Assugrin®) and a neutral (still water) placebo given double-blind will be compared in a randomized, cross-over sequence and according to our standardised procedure on four separate study days. Symptoms will be recorded using standardised questionnaires and breath concentrations of H2 and CH4 will be measured during testing on the four study days. Somatisation and psychological profiles will be assessed by questionnaires. Blood samples will be obtained before and during provocation testing to assess short-term responses to fructose loading by metabolomics. Fructose, blinded and open, and placebo responses will be compared and baseline predictors for a positive breath tests assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Fructose double-blind

Active Comparator

Fructose during breath test, double-blind 35g

干预措施: Blinded breath test with fructose (Procedure)

Fructose open

Active Comparator

Fructose during breath test, open 35g

干预措施: Open breath test with fructose (Procedure)

Sweet placebo double-blind

Placebo Comparator

Assugrin during breath test double-blind

干预措施: Breath test with sweet placebo (Assugrin) (Procedure)

Neutral placebo double-blind

Placebo Comparator

Water during breath test double-blind

干预措施: Breath test with neutral placebo (still water) (Procedure)

结局指标

主要结局

Fructose intolerance, as percentage of patients

时间窗: 5 hours

Defined by symptom scores

次要结局

  • Between-group comparisons of breath test gas concentrations and symptom indices(5 hours)
  • Correlations between breath test gas concentrations, symptom indices and metabolite(5 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

C. Wilder-Smith

Dr.

Brain-Gut Research Group

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer: ARTemIS-Eso, a three-level, open-label, phase I-II studyAdenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.MedDRA version: 20.0 Level: PT Classification code 10061534 Term: Oesophageal squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10030137 Term: Oesophageal adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-000935-42-BEInstitut Jules Bordet100
已完成
不适用
Cough Reflex Sensitivity and Bronchial Hyper-responsivenessGastroesophageal Reflux DiseaseChronic CoughBroncho-hyperreactivity
NCT01777867Mayo Clinic24
已完成
不适用
Investigation of Respiratory Functions, Exercise Endurance and Functional Capacity in Geriatric Individuals With Metabolic SyndromeMetabolic SyndromeRespiratory DiseaseExercise CapacityRespiratory Muscle
NCT06253819Kırıkkale University30
尚未招募
3 期
Study of assessment of susceptibility with focus on respiratory tract infection in age group of 18 years to 40 years.
CTRI/2021/06/034157I
已完成
不适用
Acceptability and Tolerance Study of Peptide Feed with FibreDietary Exposure
NCT06102135Société des Produits Nestlé (SPN)15